RegulatoryOfficial
EU and Japan press case for sustained medical countermeasure R&D at Tokyo session
🇪🇺 European Commission (DG SANTE) · Mon 16 Nov 2026
A policy study session hosted by DNDi in Tokyo used dengue as a case study to argue that preparedness depends on research capacity maintained between outbreaks.
The European Commission, Japan and the Drugs for Neglected Diseases initiative (DNDi) used a policy study session in Tokyo on 16 November to stress the value of sustained investment in research and development for medical countermeasures. Laurent Muschel, Deputy Head of DG HERA, attended.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Official source: European Commission (DG SANTE) ↗
Article written by VigiEye from the official source (European Commission (DG SANTE)). AI-assisted; check the source before acting.
More Regulatory
All →
Galectin files belapectin Phase 3 protocol with FDA as chairman converts $105.8M debt
🇺🇸 Galectin Therapeutics Inc (GALT) · Mon 16 Nov 2026
Apnimed's sleep apnoea drug AD109 awaits FDA decision with 28 February 2027 goal date
🇺🇸 Apnimed, Inc. (APMD) · Mon 16 Nov 2026
FDA sets 25 March 2027 goal date for Unicycive's resubmitted oxylanthanum carbonate application
🇺🇸 Unicycive Therapeutics, Inc. (UNCY) · Mon 16 Nov 2026
FDA grants orphan drug designation to Noema's basimglurant for trigeminal neuralgia
Noema Pharma AG · Mon 16 Nov 2026
FDA issues complete response letter for Summit's ivonescimab in EGFR-mutant NSCLC
🇺🇸 Summit Therapeutics Inc. (SMMT) · Mon 16 Nov 2026
Invivyd Q3 Pemgarda revenue reaches $15.4M as VYD2311 data timing shifts after FDA talks
🇺🇸 Invivyd, Inc. (IVVD) · Mon 16 Nov 2026